IVD Clause Samples

POPULAR SAMPLE Copied 1 times
IVD. 4J94-08 5002427 FG,VSeq HIV-1 Genotype Sys v2 Pack 1,IVD 4J94-07 5002428 FG,VSeq HIV-1 Genotype Sys v2 Pack 2,IVD 4J94-13 5002439 ▇▇▇▇▇▇▇ ▇▇▇-▇ ▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇.▇, ▇▇▇ 4J94-12 5002441 FG, 3100/3100Avant OM, VS HIV-1 v2, IVD New Part 5002720 FG, ViroSeq HIV-1 Integrase Kit RUO New Part 5002721 FG, ViroSeq PCR Cleanup Reagent, GPR New Part 5002722 FG, ViroSeq Sample Prep, Integrase (RUO) 4J92-66 5000184 Cystic Fibrosis Genotyping Assay CE 5001653 IFU, CF GT ASSAY v3 CAN IVD, ENGLISH 5001654 IFU, CF GT ASSAY v3 CAN IVD, FRENCH 2N05-03 5001862 IFU, CF GENOTYPING ASSAY v3 CE, ENGLISH 2N05-04 5001863 IFU, CF GENOTYPING ASSAY v3 CE, FRENCH 2N05-05 5001864 IFU, CF GENOTYPING ASSAY v3 CE, GERMAN 2N05-06 5001865 IFU, CF GENOTYPING ASSAY v3 CE, ITALIAN 2N05-07 5001866 IFU, CF GENOTYPING ASSAY v3 CE, SPANISH 2N05-08 5001867 IFU, CF GENOTYPING ASSAY v3 CE, GREEK 2N05-09 5001868 IFU, CF GENOTYPING ASSAY v3 CE, PORTUGUE 2N05-10 5001869 IFU, CF GENOTYPING ASSAY v3 CE, DANISH 2N05-11 5001870 IFU, CF GENOTYPING ASSAY v3 CE, SWEDISH 2N05-02 5001871 CF Conf Disk v2.0 for GeneMapper v3.5,CE New Part 5002253 IFU, CF GENOTYPING ASSAY v3 CE, CZE New Part 5002254 IFU, CF GENOTYPING ASSAY v3 CE, NOR New Part 5000469 INSTR MANUAL, CF GT ASSAY, US IVD 6L20-01 5001534 FG, CF GENOTYPING ASSAY, US IVD 6L20-02 5001547 USER’S MANUAL, CF GT ASSAY, US IVD 5001548 CF CONFIG DISK, GMv3.5, US IVD 2N45-01 5002000 FG, CEGA POLYMER 2N46-01 5002001 FG, HIGHLY DEIONIZED FORMAMIDE 2N47-01 5002002 FG, CEGA-16 Instrument 2N48-01 5002003 FG, CEGA 10x BUFFER 2N49-01 5002004 FG, CEGA-16 ARRAY 36cm 2N50-01 5002005 CEGA RESERVOIR FOR BUFFER-WATER-WASTE 2N51-01 5002006 CEGA RESERVOIR SEPTA 2N52-01 5002007 CEGA-16 INSTRUMENT PQ PROTOCOL New Part 5002008 CEGA-16 INSTRUMENT IQ/OQ PROTOCOL 2N57-01 5002009 CEGA INSTALLATION MANUAL 2N69-01 5002010 FG, CEGA DATA COLLECTION SOFTWARE v2.1 2N59-01 5002012 ARRAY CALIBRATION RULER 2N58-01 5002013 96-WELL PLATE BASE 2N60-01 5002014 96-WELL PLATE RETAINER New Part 5002015 96-WELL PLATE SEPTA 2N67-01 5002016 250 uL GLASS SYRINGE New Part 5002017 5.0▇▇ ▇▇▇▇▇ SYRINGE 2N71-01 5002020 CEGA-16 Instrument Site Prep/Safety New Part 5002023 Array Ferrule Sleeve PEEK 2N74-01 5002027 CEGA-16 INSTRUMENT, COMPLETE SYSTEM 2N76-01 5002028 CEGA-16 COMPUTER SYSTEM 6L20-07 5002029 CEGA, CF IVD SOFTWARE IMAGE 2N45-01 5002030 FG, GENEMAPPER SOFTWARE v3.5.4 2N46-01 5002031 96-WELL REACTION PLATE 2N47-01 5002033 SYRINGE O-RING 2N48-01 5002496 FG, CF Genotyping Assay, US IVD 2304 Kit 6L43-01...
View Source

Related to IVD

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.